OUR CONTRACEPTIVE PIPELINE

We’re committed to bringing women more contraceptive choices that can keep pace with their wants and needs. Our pipeline includes both combined hormonal contraception (CHC) and progestin-only transdermal contraceptive products. All of our current product candidates use Skinfusion®, the same patch technology as AG200-15.

Currently, all products beyond AG200-15 are on hold. Depending on the outcome of the initial Phase II clinical trial of the Small Patch (SmP) program, additional design and planning may be required for SmP pipeline products.

CHC PIPELINE

AG200-15 (SmP)
Phase I
AG200-15 (SmP)
Phase I
Phase II
Phase III
    • Designed to allow shorter, lighter periods
    • Weeks 1-3 of regimen: Same patch as AG200-15 (Twirla®), our lead product candidate
    • Week 4: Smaller, lower-dose patch

AG200-ER (SmP)
Phase I
AG200-ER (SmP)
Phase I
Phase II
Phase III
    • Extended-cycle regimen, designed to extend time between episodes of withdrawal bleeding
    • Regimen uses the same patch as AG200-15 (Twirla) and a smaller, lower-dose patch

AG200-ER
Phase I
AG200-ER
Phase I
Phase II
Phase III
    • Extended-cycle regimen, designed to extend time between episodes of withdrawal bleeding

PROGESTIN-ONLY PIPELINE

AG890
Phase II
AG890
Phase II
Phase III
    • Progestin-only contraceptive patch
    • Developed to meet broader contraceptive needs:
      • Women who are breastfeeding
      • Women at higher risk of VTE (risk factors like smoking, age > 35 years, VTE history, obesity)